JAGUAR HEALTH, INC. Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- JAGUAR HEALTH, INC. stock issued during period, value, issued for services for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- JAGUAR HEALTH, INC. stock issued during period, value, issued for services for the quarter ending 2024-09-30 was $0.00.
- JAGUAR HEALTH, INC. stock issued during period, value, issued for services for the quarter ending 2024-06-30 was $9.00K.
- JAGUAR HEALTH, INC. stock issued during period, value, issued for services for the quarter ending 2023-12-31 was $6.00K, a 200.00% increase year-over-year.
- JAGUAR HEALTH, INC. stock issued during period, value, issued for services for fiscal 2024 was $9.00K, a 94.77% decline from fiscal 2023.
- JAGUAR HEALTH, INC. stock issued during period, value, issued for services for fiscal 2023 was $172.00K, a 647.83% increase from fiscal 2022.
- JAGUAR HEALTH, INC. stock issued during period, value, issued for services for fiscal 2022 was $23.00K.
- JAGUAR HEALTH, INC. stock issued during period, value, issued for services for fiscal 2019 was $140.00K, a 2078.99% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | $9.00K 10-K · filed 2026-04-07 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | |
| 2024-06-30 | $9.00K 10-Q · filed 2025-08-14 | |
| 2023-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $172.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | |
| 2022-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $23.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | |
| 2022-06-30 | $5.00K 10-Q · filed 2023-08-14 | |
| 2022-03-31 | $14.00K 10-Q · filed 2023-05-15 | |
| 2019-12-31 | $140.00K 10-K · filed 2021-03-31 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-03 | $6.42K 10-K · filed 2020-04-03 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | |
| 2018-03-31 | $6.42K 10-Q · filed 2019-05-21 | |
| 2017-12-31 | $43.83K 10-K · filed 2019-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |